Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
Dec. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Operating Expenses | |||||||
| General, selling and administration | $ 131,359 | $ 641,942 | $ 254,404 | $ 986,683 | $ 1,595,936 | $ 1,323,552 | $ 405,556 |
| Product development costs | 122,551 | 1,162,879 | 217,761 | 1,217,901 | 1,625,075 | 408,640 | 416,304 |
| Professional fees | 429,246 | 208,957 | 466,550 | 437,234 | 523,389 | 451,064 | 244,430 |
| Loss from Operations | 683,156 | 2,013,778 | 938,715 | 2,641,818 | 3,744,400 | 2,183,256 | 1,066,290 |
| Other Expenses | |||||||
| Recovery of expense | (86,236) | ||||||
| Interest expense | 525,636 | 1,586,936 | 1,044,627 | 2,082,829 | 5,261,137 | 1,938,877 | 1,861,971 |
| Total other expenses | 525,636 | 1,586,936 | 1,044,627 | 2,082,829 | 5,261,137 | 1,938,877 | 1,775,735 |
| Net loss | $ (1,208,792) | $ (3,600,714) | $ (1,983,342) | $ (4,724,647) | $ (9,005,537) | $ (4,122,133) | $ (2,842,025) |
| Loss per share, basic and diluted | $ (0.00) | $ (0.01) | $ (0.01) | $ (0.02) | $ (0.04) | $ (0.02) | $ (0.01) |
| Weighted average number of shares of common stock outstanding, basic and diluted | 270,777,909 | 245,955,687 | 270,291,721 | 244,366,798 | 256,668,320 | 242,777,909 | 242,777,909 |
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|